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Abstract
The aims of this study were first to clearly define two different entities: locoregional
recurrences and limited metastatic disease and secondly to evaluate the place
of extensive surgery in these two types of recurrence. Material and Methods.
Twenty-four patients were followed from June 2004 until May 2014. All patients
underwent surgery but for 1 patient this surgery was stopped because the
tumour was unresectable. Results. The median interval between surgery for the
primary tumour and the locoregional recurrence or metastatic evolution was 129
months. Eight patients had pure nodal recurrences, 4 had nodal and muscular
recurrences, 5 had muscular + skin recurrences, and 8 had metastatic evolution.
Currently, all patients are still alive but 2 have liver metastases. Disease free
survival was measured at 2 years and extrapolated at 5 years and was 92% at
these two time points. No difference was observed for young or older women;
limited metastatic evolution and locoregional recurrenc...
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The aims of this study were first to clearly define two different entities: locoregional recurrences and limited metastatic disease and
secondly to evaluate the place of extensive surgery in these two types of recurrence. Material and Methods. Twenty-four patients
were followed from June 2004 until May 2014. All patients underwent surgery but for 1 patient this surgery was stopped because the
tumour was unresectable. Results. The median interval between surgery for the primary tumour and the locoregional recurrence
or metastatic evolution was 129 months. Eight patients had pure nodal recurrences, 4 had nodal and muscular recurrences, 5
had muscular + skin recurrences, and 8 had metastatic evolution. Currently, all patients are still alive but 2 have liver metastases.
Disease free survival was measured at 2 years and extrapolated at 5 years and was 92% at these two time points. No difference
was observed for young or older women; limited metastatic evolution and locoregional recurrence exhibited the same disease free
survival. Conclusion. Extensive surgery has a place in locoregional and limited metastatic breast cancer recurrences but this option
must absolutely be integrated in themultidisciplinary strategy of therapeutic options and needs to be planned with a curative intent.
1. Introduction
Locoregional recurrences and limited metastatic disease rep-
resent a very complex challenge in the treatment of breast
cancer. There is absolutely no consensus in the literature
about the management of these entities, as there are many
retrospective studies and no multicentric studies. More-
over, there is a big confusion between local recurrences,
locoregional recurrences, new primary cancer, and limited
metastatic disease. Recently, 24 experts from the Maastricht
Breast Cancer Endpoint Consensus Group [1] defined local
recurrences, second primary breast cancer, locoregional
recurrences, andmetastatic disease. According to the experts,
local events are represented by events in the ipsilateral
breast, the scar, and cutaneous nodes.These local recurrences
are excluded from our study. Locoregional events con-
cern ipsilateral nodes, axillary, infraclavicular, subclavicular,
retropectoral, and internal mammary nodes (and alsomuscle
recurrences in the pectoralis major and pectoralis minor).
Distant recurrences, in fact metastatic evolution, concern
invasion of contralateral nodes and of the sternal bone.
The aims of the study were to correctly and clearly define
locoregional recurrences and limited metastatic disease. The
second aim was to study the place of an extensive surgical
approach in the therapeutic strategy and to evaluate its impact
on disease free survival (DFS) and overall survival (OS).
2. Material and Methods
We performed our study on 24 consecutive patients followed
from June 2004 to May 2014 for locoregional breast cancer or
limited metastatic disease (chest wall) in our institution. The
local ethics committee approved this study and the patients
gave written informed consent to publish these data.The pro-
cedure to obtain a clinicaltrials.gov (http://clinicaltrials.gov/)
identifier is currently ongoing.
After their primary breast tumour at this time, the
patients were not yet included in our study; all patients were
followed by clinical examination and blood tests every 3
months for 2 years, then every 6months for 5 years and yearly
thereafter, and yearly by breast mammogram and ultrasound.
Breast MRI was added in case of suspicion of recurrence.
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Figure 1: Subclavicular, retropectoral, and axillary dissection for
axillary and subclavicular recurrence.
Figure 2: Resection of the anterior chest wall: inferior sternal bone
and ribs (2, 3, 4, and 5) resection for large tumour involvement of
the sternal area.
After histological diagnosis of recurrence, the examination
was completed by CT-scan of the chest and abdomen and
bone scintigraphy. In case of metastatic evolution, PET-
CT was also performed. In some cases, MRI of the bone
marrow was also added. After treatment of the locoregional
or metastatic recurrence, patients were followed every 3
months for 2 years and thereafter every 6 months according
to the same modalities of follow-up (CT chest + abdomen,
bone scan, blood tests, breast mammography + ultrasound,
and systematically MRI).
Statistical analysis was performed using R Core Team.
(R: A language and environment for statistical computing. R
Foundation for Statistical Computing, Vienna, Austria, 2014
URL http://www.R-project.org/).
Kaplan-Meier curves were generated to calculate DFS.
3. Results
(a) Characteristics of the primary tumour and of the patients
are described in Table 1. 24 patients were included in this
study. A majority of them (62.5%) were menopausal. Sixteen
out of the 26 initial surgical procedures were radical (2
bilateral mastectomies). Nine surgeries resulted in an axil-
lary node-positive staging. All but one tumour had been
endocrine receptor positive. Eighteen tumours benefited
from adjuvant radiotherapy. Seven patients were treated with
Figure 3: Low modification of carcinomatous infiltration of sternal
bone as well as of the cartilage of the rib. The glandular neoplastic
cells infiltrate and destroy the bone (indicated by arrows) and the
cartilage (indicated by a star) (haematoxylin eosin staining, barr:
500 microns).
Figure 4: Histological view of pericardial infiltration, showing nests
of neoplastic cells into the adipous tissue. The inked margin is free
(Hematoxylin and Eosin staining, barr = 250 microns).
adjuvant chemotherapy and all patients were treated with
adjuvant endocrine therapy.
(b) Characteristics of the recurrences (locoregional recur-
rences or metastatic evolution) are described in Table 2.
At the time of their recurrence, only 2 patients were still
premenopausal. The median interval between the initial
occurrence of breast cancer and the recurrence was 129
months (range 24–286months). Two recurrences were estro-
gen receptor negative.
Of note, local recurrences were excluded from this
study. Locoregional recurrence andmetastatic evolutionwere
defined according to the criteria of the Maastricht Group,
Figure 1.
Eight patients had pure nodal recurrences, 4 had nodal
+ muscular recurrences (invasion of the pectoralis major),
5 had muscular and skin recurrences, and 8 had metastatic
evolution (bone invasion, pleural effusion, etc.) Figures 2, 3
and 4.
(c) Staging of the disease is described in Table 2. All
patients had breast MRI and CT-scan of the chest wall and of
the abdomen. Twenty-two patients were additionally staged
with PET-CT and 7 with MRI of the bone marrow.
(d) Morbidity of the surgical procedure was very low, as
only 2 patients had a limited necrosis of latissimus dorsi flaps.
(e) Systemic therapies administered at the time of recur-
rence are mentioned in Table 3.
Systemic therapywas discussed duringweeklymultidisci-
plinary tumour board meetings. Surgery was thus integrated
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Table 1: Patients’ and tumours’ characteristics at initial breast surgery.
Age
(i) <50 6
(ii) ≥50 18
Premenopausal status 9
Menopausal status 15
Histological subtypes (26 tumours analysed, 2 bilateral breast cancers)
Grade
(i) Grade I: 2
(ii) Grade II: 18
(iii) Grade III: 6
Hormonal receptors
(i) ER (+): 25
(ii) PR (+): 22
(iii) ER (−) + PR (−): 1 (DCIS grade III)
(i) Infiltrating ductal carcinoma 19
(ii) Mixed lobular and ductal carcinoma 2
(iii) Infiltrating lobular carcinoma 4
(iv) Pure DCIS 1
Initial breast surgery
(i) Surgical procedures 26
(ii) Breast-conserving surgery 10
(iii) Mastectomy (2 bilateral) 16
Axillary dissection performed in 26 cases
(i) Negative nodes 17
(ii) Positive nodes 9
Quality of resection
(i) R0 25
(ii) R1 (1mm DCIS) 1
Adjuvant therapy
(i) Radiotherapy
(a) Yes 18
(b) No 8
(ii) Chemotherapy
(a) Yes 7
(b) No 17
Endocrine therapy (24 patients)
(i) Tamoxifen 22
(ii) Tamoxifen + GnRH agonist 1
(iii) Aromatase inhibitors 1
R0: complete resection of any visible tumour with a pathologic demonstration of negative resection margins.
R1: complete resection of any visible tumour with a pathologic demonstration of positive margins.
ER: estrogen receptor.
PR: progesterone receptor.
in a multimodality approach. A total of 20 patients received
chemotherapy. Two options were discussed: either upfront
surgery or initial chemotherapy. Fourteen out of the 24
patients received radiotherapy (50Gy in case of mastectomy
and 60Gy in case of lumpectomy). For 6 patients, this actually
was a second course of radiotherapy but overlap of the fields
concerned only 1 patient who therefore received her second
course of radiotherapy by brachytherapy.
For the 5 other patients who were administered a second
course of radiotherapy, the first course of radiotherapy had
only been administered on the breast and not on the nodal
areas. There was thus no overlap of the fields. Twenty-two
patients received endocrine therapy, which is still in progress
for 20 of them. It was stopped for 2 patients with metastatic
evolution (hepatic evolution). One of them received taxanes
(6 courses) and thereafter, capecitabine, which is still in
progress. The second patient with hepatic evolution is still
receiving capecitabine.
(f) Survival Rates. With a median follow-up of 40.7
months (5–120 months), this study has a relatively short
follow-up.
All patients were still alive at the time of database lock but
2 patients had a metastatic evolution with liver involvement.
These liver metastases were treated by chemotherapy and the
2 patients currently have stable disease.
DFSwas calculated using Kaplan-Meier curves. No statis-
tical difference was observed for young versus older patients
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Table 2: Patients’ and tumours’ characteristics at the time of recurrence.
Age
(i) <50 2
(ii) ≥50 22
Premenopausal status 2
Menopausal status 22
Free interval between primary tumour and recurrence (months)
(i) Median duration 129
(ii) Range 24–242
Histological subtypes (24 tumours analyzed) Grade
(i) Infiltrating ductal carcinoma 18 (i) Grade I: 0
(ii) Infiltrating lobular carcinoma 4 (ii) Grade II: 7
(iii) Mixed 2 (iii) Grade III: 17
Endocrine status
(i) ER (+) 22
(ii) PR (+) 20
(iii) ER and PR (−) 2
Node dissection (24 patients)
(i) Axillary retropectoral dissection 14
(ii) Mediastinal intramammary chain dissection 7
(iii) Node dissection not performed 3
(iv) Bone resection (sternal and rips resection)
(a) Yes 7
(b) No 17
Margin
(i) R0 21
(ii) R1 2
(iii) Stop surgery for unresectable lesion 1
(iv) Bone infiltration
(a) Yes (bone and rips) 7
(b) No 17
Staging of the disease
(i) Breast MRI 24
(ii) Abdominal and chest wall CT-scan 24
(iii) PET-CT 22/24
(iv) MRI of bone narrow 7
Morbidity of the surgery 2 limited necroses of flaps
and there was no difference between limited metastatic
evolution and locoregional recurrences (Figures 5, 6 and 7).
4. Discussion
This study emphasizes the importance of a careful definition
of locoregional recurrence and metastatic evolution (limited
to the chest wall). Patients with local recurrences were
excluded from this study.
The question of the exact incidence of this disease entity
could unfortunately not be entirely resolved by this study, as
some patients were referred by other cancer centres at the
moment of their recurrence.
Locoregional recurrences can occur both after mastec-
tomy and after breast-conserving surgery. In the past, the
incidence was estimated between 5 and 40% [2]. Fortunately,
the locoregional recurrence rate following breast cancer
surgery has decreased with time [3]. This decrease is due to
increased screening leading to the diagnosis of less advanced
disease and to adjuvant therapies such as radiotherapy and
also systemic therapies such as chemotherapy and endocrine
therapy. This has been demonstrated in a retrospective study
[3] that included 1,143 women younger than 40 years old
with early breast cancer who underwent breast-conserving
therapy in the South of the Netherlands between 1988 and
2010. After a median follow-up of 8.5 years, 186 patients
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Figure 5: Disease free survival of all patients/locoregional recur-
rences and limited metastatic disease.
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Figure 6: Disease free survival according to age (age <50 years and
≥50 years).
had developed an isolated locoregional recurrence. The 5-
year locoregional recurrence rate for the subgroup treated
in the periods 1988–1998, 1999–2005, and 2006–2012 was,
respectively, 9.8%, 5.9%, and 3.3%. In a multivariate analysis,
adjuvant systemic therapy was associated with a reduction in
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Figure 7: Comparison of the disease free survival between locore-
gional recurrence and limited metastatic disease.
Table 3: Systemic treatment modalities at the time of recurrence.
External radiotherapy
(i) Yes 13
(ii) No 10
Brachytherapy 1
Chemotherapy
(i) First 4
(ii) After surgical procedure 16
Endocrine therapy (22 patients)
(i) Aromatase inhibitors
22
20/22 (still in progress)
2/22 (stopped in patients
with metastatic evolution)
the risk of locoregional recurrence of almost 60%.The locore-
gional recurrence rate is slightly lower after mastectomy than
after breast-conserving therapy [4–6].
In the database of our breast cancer center (unpub-
lished data), we observed the same decrease in locoregional
recurrences over time. Between 2000 and 2005, the 5-year
locoregional recurrence rate was 4% after breast-conserving
surgery and mastectomy; it dropped to 2.5% between 2006
and 2011 [7]. These results are similar to those observed in
the literature.
Careful staging of recurrences (locoregional and metas-
tases of the chest wall) represents a crucial step in the
management of these patients. In case ofmetastatic evolution,
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we cannot stress enough the importance of the preoperative
management with CT-scan and PET-CT and of a multidis-
ciplinary approach. Breast imaging (breast MRI, ultrasound)
plays a major role in the identification and the localization of
the recurrence.
Thanks to these careful screening procedures, we only
had 2 undiagnosed pleural and pericardial effusions in our
series (Figure 1); free margins were obtained for all patients
except for these 2 patients. The results of our series, which is
very small, are in general better than those published in the
literature [7]. We therefore insist on the preoperative staging
and the importance of the multidisciplinary approach. We
think that resection of the chest wall with sternal bone and
ribs (Figures 2 and 3) must be limited to patients treated with
a curative intent and must not be considered as a palliative
option [8–10].
The main objective of this extensive surgery is to achieve
free margins in case of locoregional recurrences and in
case of metastatic evolution. This highlights the importance
of the surgical procedure. In all surgical procedures, the
surgical resection is performed by a multidisciplinary team
comprising a reconstructive plastic surgeon, a breast surgeon
and, in case of thoracic invasion, a thoracic surgeon.
For nodal recurrences, we observed that the great major-
ity of nodal recurrences are axillary and retropectoral. One
case of subclavicular recurrence was also observed. In all
cases, the three areas are explored in an attempt to obtain
free margins (Figure 4). This was achieved in all cases. These
results are similar to those reported in the literature.
The first therapeutic option, in case of isolated nodal
recurrence, is to perform surgery [7, 11].
In case of muscular invasion, myocutaneous flaps are
very often used to cover the defects and also to assure clear
margins (aim achieved).
As described in the literature by Friedel, we think that
the surgeons’ expertise can improve survival and decrease
morbidity [8, 9].
In our study, morbidity is very low because we only
observed 2 limited necroses of latissimus dorsi flaps, treated
by local care. No reintervention was necessary.
Follow-up of our study is short and the number of patients
is small. Until now, we observe excellent results in terms of
survival rate and disease free survival.
Our results are in agreement with the best results
observed in the literature [8] and better than some studies,
with a 5-year DFS at 92% (Figure 5). We think that careful
preoperative staging and exact definition of locoregional
recurrences and metastatic evolution are important because,
in many manuscripts, there is a confusion between these 2
entities [8, 9].
This study is too small to clearly identify prognostic
factors. As in Friedel’s study, young age is not associated with
bad prognosis (Figure 6).
If the patient has not previously received radiotherapy,
radiation must be administered postoperatively, as already
proposed by most authors. The irradiation involves the chest
wall and the lymph nodes [12–15].
If the patient has undergone previous irradiation, the
problem of the toxicity must be debated. In our institution,
we do not repeat radiotherapy, except for brachytherapy.Only
one patient had overlap of the fields. The other patients who
had previously received radiotherapy were readministered
radiotherapy but essentially on the axillary subclavicular
and internal mammary nodes, which were not previously
irradiated. It appears that irradiating with small doses could
be recommended [13]. Photodynamic therapy is dedicated to
skin cancer and its use in the context of locoregional recur-
rence is limited. Currently, only small series have studied this
therapeutic option [16, 17].
In our series, limited metastatic invasion of the chest wall
did not exhibit worse prognosis (Figure 7) than locoregional
recurrences. The M1 status should thus not discourage the
multidisciplinary team from proposing extensive surgery
with a curative intent.
5. Conclusions
The results of our small study are very encouraging con-
cerning disease free survival. This is the main information
derived from this study. Our study needs to be completed by a
prolonged follow-up and by an increased number of patients
with a prospective follow-up. By the end of the year, 10 new
patients will be added.
This study highlights the importance of the preoperative
staging in an attempt to obtain free margins during the
extensive surgery. The absolute necessity of a multidisci-
plinary team for the therapeutic decision and for the surgical
procedures is also required to define the best therapeutic
option for each patient.
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